Rybrevant Market Report 2026

Rybrevant Market Overview

• The Rybrevant market growth in the historic period has been driven by rising incidence of non-small cell lung cancer, advancements in molecular diagnostics • Market expansion is supported by increasing demand for personalized cancer treatment, expansion of genomic testing in oncology • Growth Driver: Rising Cancer Incidence Drives Growth In Market • Market Trend: Innovative Therapies For Non-Small Cell Lung Cancer (NSCLC) • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Rybrevant Market?

Rybrevant (amivantamab) is a monoclonal antibody used to treat non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. It works by targeting and inhibiting the EGFR and MET receptors to slow cancer growth and spread. The main clinical indication of rybrevant include non-small cell lung cancer (nsclc) with met amplification, broader EGFR-mutated nsclc, and combination therapies for advanced or metastatic nsclc. Non-small cell lung cancer (NSCLC) with MET amplification refers to a subset of NSCLC where there is an abnormal increase in the number of copies of the MET gene. The MET gene encodes the hepatocyte growth factor receptor (HGFR), which plays a role in tumor growth, metastasis, and resistance to therapy. The several treatment lines include first-line; second-line, and monotherapy for nsclc with egfr mutations and various route of administrations involved are intravenous infusion, and subcutaneous injection and are distributed through multiple channels such as hospitals, and specialty pharmacies.

What Is The Rybrevant Market Growth Forecast?

The growth in the forecast period can be attributed to increasing demand for personalized cancer treatment, expansion of genomic testing in oncology, growing investment in biologic drug development, rising adoption of combination cancer therapies, continued innovation in antibody-based treatments. Major trends in the forecast period include increasing adoption of targeted oncology therapies, rising use of monoclonal antibodies in lung cancer, growing focus on precision medicine approaches, expansion of biomarker-driven cancer treatments, enhanced development of combination oncology regimens.

Global Rybrevant Market Segmentation

1) By Clinical Indication: Non-Small Cell Lung Cancer (NSCLC) With MET Amplification, Broader EGFR-Mutated NSCLC, Combination Therapies For Advanced Or Metastatic NSCLC 2) By Treatment Line: First-Line, Second-Line, Monotherapy For NSCLC With EGFR Mutations 3) By Route Of Administration: Intravenous Infusion, Subcutaneous Injection 4) By Distribution Channel: Hospitals, Specialty Pharmacies

What Is The Driver Of The Rybrevant Market?

The increasing number of cancer patients is expected to propel the growth of the rybrevant market going forward. Cancer patients refer to individuals who have been diagnosed with cancer, a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. The rising number of cancer patients can be attributed to an aging population, as older individuals are more susceptible to developing cancer, and improved diagnostic methods, which have enhanced the early detection and reporting of cancer cases. Rybrevant is used to treat non-small cell lung cancer by targeting EGFR and MET proteins, specifically in patients with EGFR exon 20 insertion mutations, to inhibit tumor growth and activate the immune response. For instance, in May 2024, according to the Canadian Cancer Society, a Canada-based national cancer charity, in 2024, in Canada, 32,100 people were diagnosed with lung cancer, accounting for 23.5% of all cancer-related deaths. Notably, lung cancer cases among females rose from 15,800 cases in 2023 to 17,300 cases in 2024. Therefore, the increasing number of cancer patients is driving the growth of the rybrevant industry.

Key Players In The Global Rybrevant Market

Major companies operating in the rybrevant market are Johnson & Johnson Service Inc.

Global Rybrevant Market Trends and Insights

Major companies operating in the rybrevant market are focusing on developing innovative solutions, such as targeted therapies for non-small cell lung cancer (NSCLC), to meet the rising demand for precision oncology, improved treatment efficacy, and options for patients with rare genetic mutations. Targeted therapies for NSCLC are advanced treatments designed to act on specific molecular alterations in cancer cells, enabling precise tumor inhibition while reducing harm to healthy tissues. For instance, in March 2024, Johnson & Johnson Inc., a Canada-based pharmaceutical company, received FDA approval for Rybrevant (amivantamab-vmjw) as a first-line treatment for NSCLC patients with particular EGFR mutations. Rybrevant is a bispecific antibody therapy composed of engineered molecules that simultaneously target EGFR and MET pathways, helping block tumor growth, overcome resistance mechanisms, and improve overall survival outcomes. It offers enhanced functionality compared to traditional chemotherapy by delivering mutation-specific action, better tolerability, and improved progression-free survival.

What Are Latest Mergers And Acquisitions In The Rybrevant Market?

In April 2025, Janssen-Cilag, a Belgium-based pharmaceutical company, partnered with Halozyme Therapeutics to develop subcutaneous oncology formulations using ENHANZE technology. With this collaboration, Janssen deepens its strategic platform by enabling more patient-friendly, rapid subcutaneous administration of RYBREVANT, reducing infusion times and potentially improving adoption and access. Halozyme is a U.S.-based provider of proprietary drug delivery enzyme technology that facilitates subcutaneous delivery of biologics.

Regional Insights

North America was the largest region in the rybrevant market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Rybrevant Market?

The rybrevant market consists of sales of products including targeted therapy drugs, immunotherapy drugs, chemotherapy drugs, and angiogenesis inhibitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Rybrevant Market Report 2026?

The rybrevant market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the rybrevant industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.